The aims of our study were to elucidate the role of S100P in vascular invasion, ETR, and HCC prognosis, to investigate the relationships between S100P expression and the p53 and β-catenin mutations, and to evaluate S100P as a predictive biomarker for survival in HCC patients with high tumor stage or ETR. This evidence concerns the gene S100P and hepatocellular carcinoma.